Testing effectiveness (Phase 2)Study completedNCT04039113What this trial is testingTezepelumab COPD Exacerbation StudyWho this might be right forChronic Obstructive Pulmonary Disease (COPD) AstraZeneca 337
Post-approval studies (Phase 4)Study completedNCT01966107What this trial is testingEvaluate the Effect of Aclidinium Bromide on Long-term Cardiovascular Safety and Exacerbations in Moderate to Very Severe COPD Patients.Who this might be right forCOPDChronic Obstructive Pulmonary DiseaseModerate to Very Severe COPD AstraZeneca 3,635
Testing effectiveness (Phase 2)Looking for participantsNCT07082738What this trial is testingInvestigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary DiseaseWho this might be right forChronic Obstructive Pulmonary Disease (COPD) AstraZeneca 1,160
Large-scale testing (Phase 3)Study completedNCT02465567What this trial is testingStudy to Assess the Efficacy and Safety of PT010 Relative to PT003 and PT009 in Subjects With Moderate to Very Severe COPD (Ethos)Who this might be right forCOPD Pearl Therapeutics, Inc. 8,588
Large-scale testing (Phase 3)Study completedNCT03162055What this trial is testingEfficacy and Safety of Glycopyrronium/Formoterol Fumarate Fixed-dose Combination Relative to Umeclidinium/Vilanterol Fixed-dose Combination Over 24 Weeks in Patients With Moderate to Very Severe Chronic Obstructive Pulmonary DiseaseWho this might be right forChronic Obstructive Pulmonary Disease COPD AstraZeneca 1,119
Testing effectiveness (Phase 2)WithdrawnNCT01043601What this trial is testingEfficacy and Safety of Two Doses of Formoterol Fumarate MDI (PT005) in Patients With Stable Chronic Obstructive Pulmonary Disease (COPD), Compared to Foradil® Aerolizer® as an Active ControlWho this might be right forCOPD Pearl Therapeutics, Inc.
Large-scale testing (Phase 3)Study completedNCT01854658What this trial is testingMulti-Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD (PINNACLE 2)Who this might be right forChronic Obstructive Pulmonary Disease (COPD) Pearl Therapeutics, Inc. 1,615
Large-scale testing (Phase 3)Study completedNCT04053634What this trial is testingEfficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With a History of Frequent ExacerbationsWho this might be right forChronic Obstructive Pulmonary Disease AstraZeneca 689
Large-scale testing (Phase 3)Study completedNCT02155660What this trial is testingEfficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With Exacerbation HistoryWho this might be right forModerate to Very Severe Chronic Obstructive Pulmonary Disease AstraZeneca 2,255
Not applicableStudy completedNCT02128529What this trial is testingEpidemiology of Chronic Bronchitis in Patients With Chronic Obstructive Pulmonary Disease (COPD)Who this might be right forChronic Obstructive Pulmonary DiseaseChronic Bronchitis AstraZeneca 976
Large-scale testing (Phase 3)Study completedNCT01782326What this trial is testingQVA vs. Salmeterol/Fluticasone, 52-week Exacerbation Study, FLAME (EFfect of Indacaterol Glycopyronium Vs Fluticasone Salmeterol on COPD Exacerbations)Who this might be right forChronic Obstructive Pulmonary Disease (COPD) Novartis Pharmaceuticals 3,362
Large-scale testing (Phase 3)Study completedNCT02497001What this trial is testingA Randomized, Double-Blind, Parallel-Group, 24-Week, Chronic-Dosing, Multi-Center Study to Assess the Efficacy and Safety of PT010, PT003, and PT009 Compared With Symbicort® Turbuhaler® (Kronos)Who this might be right forCOPD Pearl Therapeutics, Inc. 1,902
Large-scale testing (Phase 3)Study completedNCT02296138What this trial is testingComparing the Efficacy of Tiotropium + Olodaterol (5/5 µg) Fixed Dose Combination (FDC) Over Tiotropium 5µg in Reducing Moderate to Severe Exacerbations in Patients With Severe to Very Severe Chronic Obstructive Pulmonary Disease.Who this might be right forPulmonary Disease, Chronic Obstructive Boehringer Ingelheim 7,903
Large-scale testing (Phase 3)Study completedNCT05573464What this trial is testingAssess the Safety of Budesonide/Glycopyrronium/Formoterol Fumarate With a Next-Generation Propellant in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary DiseaseWho this might be right forChronic Obstructive Pulmonary Disease (COPD) AstraZeneca 559
Large-scale testing (Phase 3)Study completedNCT05046795What this trial is testingRevefenacin in Chinese Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease(COPD)Who this might be right forCOPD Mylan Pharma UK Ltd. 258
Large-scale testing (Phase 3)Study completedNCT02268396What this trial is testingGlycopyrronium and Formoterol Fumarate (GFF) Metered Dose Inhaler (MDI) Dose Indicator Study in Adults With Moderate to Very Severe COPDWho this might be right forCOPD Pearl Therapeutics, Inc. 138
Large-scale testing (Phase 3)Study completedNCT02766608What this trial is testingStudy to Assess Efficacy and Safety of PT009 Compared to PT005, PT008, and Symbicort® Turbuhaler® on Lung Function Over 24-Weeks in Subjects With Moderate to Very Severe COPDWho this might be right forChronic Obstructive Pulmonary Disorder Pearl Therapeutics, Inc. 2,389
Not applicableStudy completedNCT04168775What this trial is testingPeak Inspiratory Flow Rates in Patients With COPDWho this might be right forCOPD University of North Carolina, Chapel Hill 80
Large-scale testing (Phase 3)Study completedNCT02343458What this trial is testingStudy to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPDWho this might be right forChronic Obstructive Pulmonary Disease Pearl Therapeutics, Inc. 1,756
Large-scale testing (Phase 3)Study completedNCT02536508What this trial is testingStudy to Assess the Safety and Tolerability of PT010, PT009 and PT003 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary DiseaseWho this might be right forCOPD Pearl Therapeutics, Inc. 627